Novartis announces licensing of pradigastat to Anji Pharmaceuticals

Anji Pharmaceuticals announced it has licensed pradigastat, an inhibitor of acyl coA: diacylglycerol acyl transferase , from Novartis. Pradigastat is a well-characterized molecule which has progressed to Phase 3 clinical testing. Anji has secured rights to pursue new indications for pradigastat, with an initial focus on regulatory approval in China. In exchange, Anji has agreed to make a one-time upfront payment of $2.0M to Novartis, with additional cash payments and downstream royalties due upon reaching regulatory and sales milestones.
https://thefly.com/landingPageNews.php?id=2838973